Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)

医学 达帕格列嗪 临床终点 安慰剂 肾脏疾病 不利影响 内科学 心力衰竭 随机对照试验 2型糖尿病 肾功能 泌尿科 急性肾损伤 糖尿病 重症监护医学 恩帕吉菲 内分泌学 病理 替代医学
作者
John J.V. McMurray,David C. Wheeler,Bergur V. Stefánsson,Ricardo Correa‐Rotter,Glenn M. Chertow,Tom Greene,Fan Fan Hou,Magnus Lindberg,Peter Rossing,C. David Sjöström,Robert D. Toto,Ann Maria Langkilde,Hiddo J L Heerspink
出处
期刊:Journal of Cardiac Failure [Elsevier BV]
卷期号:26 (12): 1111-1111 被引量:1
标识
DOI:10.1016/j.cardfail.2020.11.024
摘要

Background Patients with chronic kidney disease (CKD) are at high risk of adverse renal and cardiovascular (CV) outcomes, particularly heart failure. We investigated the effects of dapagliflozin inpatients with CKD, with and without type 2 diabetes (T2D). DAPA-CKD is the first trial to test the effects of a SGLT2 inhibitor on renal and CV outcomes in CKD patients without T2D and included patients with a lower eGFR than in prior trials. Methods We enrolled CKD patients with and withoutT2D with estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73m2 and UACR200-5000 mg/g, randomized (1:1) to dapagliflozin (10 mg once daily) or placebo. Patients were maintained on a stable dose of ACE inhibitor or ARB for ≥4 weeks before screening, if not contraindicated. The primary composite endpoint was worsening of kidney function (≥50% decline in eGFR, occurrence of end-stage kidney disease [ESKD]), or renal or CV death. Secondary endpoints were (in hierarchical order): (1) renal composite (primary endpoint without CV death); (2) composite of CV death or hospitalization for heart failure (hHF); and (3) death from any cause. The trial was stopped early following routine review by the data monitoring committee, because of overwhelming evidence of efficacy. Results Overall, 4304 patients were randomized at386 centers in 21 countries; 2152 to dapagliflozin, 2152 to placebo. The mean age was 62 years and 67% were male. Mean eGFR was 43.1 mL/min/1.73m2 and mean UACR was 949 mg/g. At baseline, 2906 (67.5%) patients had T2D, 96% had a history of hypertension, 37% other CV disease, and 11% heart failure. 4174(97%) were receiving an ACEi/ARB or another renin-angiotensin system blocker. Baseline characteristics were balanced between treatment groups. The sponsor has announced that in DAPA-CKD the primary and each of the secondary endpoints was reduced significantly by dapagliflozin compared with placebo. Conclusions Dapagliflozin significantly reduced the risk of CKD progression, the incidence of CV death/hHF, and prolonged survival in patients with CKD, with and without T2D. This presentation will report the prespecified primary and secondary outcomes in detail, along with additional information on heart failure outcomes. (Funded by AstraZeneca; NCT03036150) Patients with chronic kidney disease (CKD) are at high risk of adverse renal and cardiovascular (CV) outcomes, particularly heart failure. We investigated the effects of dapagliflozin inpatients with CKD, with and without type 2 diabetes (T2D). DAPA-CKD is the first trial to test the effects of a SGLT2 inhibitor on renal and CV outcomes in CKD patients without T2D and included patients with a lower eGFR than in prior trials. We enrolled CKD patients with and withoutT2D with estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73m2 and UACR200-5000 mg/g, randomized (1:1) to dapagliflozin (10 mg once daily) or placebo. Patients were maintained on a stable dose of ACE inhibitor or ARB for ≥4 weeks before screening, if not contraindicated. The primary composite endpoint was worsening of kidney function (≥50% decline in eGFR, occurrence of end-stage kidney disease [ESKD]), or renal or CV death. Secondary endpoints were (in hierarchical order): (1) renal composite (primary endpoint without CV death); (2) composite of CV death or hospitalization for heart failure (hHF); and (3) death from any cause. The trial was stopped early following routine review by the data monitoring committee, because of overwhelming evidence of efficacy. Overall, 4304 patients were randomized at386 centers in 21 countries; 2152 to dapagliflozin, 2152 to placebo. The mean age was 62 years and 67% were male. Mean eGFR was 43.1 mL/min/1.73m2 and mean UACR was 949 mg/g. At baseline, 2906 (67.5%) patients had T2D, 96% had a history of hypertension, 37% other CV disease, and 11% heart failure. 4174(97%) were receiving an ACEi/ARB or another renin-angiotensin system blocker. Baseline characteristics were balanced between treatment groups. The sponsor has announced that in DAPA-CKD the primary and each of the secondary endpoints was reduced significantly by dapagliflozin compared with placebo. Dapagliflozin significantly reduced the risk of CKD progression, the incidence of CV death/hHF, and prolonged survival in patients with CKD, with and without T2D. This presentation will report the prespecified primary and secondary outcomes in detail, along with additional information on heart failure outcomes. (Funded by AstraZeneca; NCT03036150)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
丘比特的应助被chi采纳,获得10
1秒前
搜集达人的应助被周博士采纳,获得10
1秒前
zrl完成签到,获得积分20
1秒前
wanci的应助被周博士采纳,获得10
2秒前
fwfl250完成签到,获得积分20
2秒前
田様的应助被周博士采纳,获得10
2秒前
2秒前
2秒前
2秒前
田様的应助被策略采纳,获得10
2秒前
FashionBoy的应助被qlz采纳,获得10
2秒前
wengarak完成签到,获得积分20
2秒前
cindy发布了新的文献求助10
3秒前
烟花的应助被Echo采纳,获得10
4秒前
天天快乐的应助被CarryLJR采纳,获得30
4秒前
4秒前
华仔的应助被CC采纳,获得10
4秒前
5秒前
123完成签到,获得积分10
5秒前
鲤鱼平安发布了新的文献求助10
5秒前
烟花的应助被李李李采纳,获得10
5秒前
5秒前
青山发布了新的文献求助10
5秒前
yuyuan完成签到,获得积分10
6秒前
wyc发布了新的文献求助10
6秒前
懒洋洋发布了新的文献求助10
6秒前
无花果的应助被不想上班采纳,获得10
7秒前
7秒前
搜集达人的应助被moonlight采纳,获得10
7秒前
希望天下0贩的0的应助被asl采纳,获得20
7秒前
7秒前
7秒前
氮气发布了新的文献求助10
8秒前
小猫咪关注了科研通微信公众号
8秒前
zkylh的应助被知许采纳,获得10
8秒前
万能图书馆的应助被一十六采纳,获得30
9秒前
syvshc的应助被科研包采纳,获得10
9秒前
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178203
求助须知:如何正确求助?哪些是违规求助? 9568998
关于积分的说明 21802098
捐赠科研通 7773088
什么是DOI,文献DOI怎么找? 3432711
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478259